Filing Flows › Century Therapeutics (IPSC) › Q1 2025 › vs Q4 2024
Century Therapeutics (IPSC) Q1 2025 vs Q4 2024 (quarter over quarter)
Century Therapeutics's revenue rose $105M (26×) from $4.2M in Q4 2024 to $109M in Q1 2025. Operating margin 67.9% against -893.5% (+961.4 pts).
Century Therapeutics, Q1 2025: revenue $109M (128× year over year), operating margin 67.9%, net earnings $76.6M, operating cash flow −$34.6M. The chart draws each line against Q4 2024, the increases inside each band.
Margins
| Q1 2025 | Q4 2024 | Change | |
|---|---|---|---|
| Operating margin | 67.9% | -893.5% | +961.4 pts |
| Net margin | 70.1% | -864.4% | +934.6 pts |
Every line
| Line | Q1 2025 | Q4 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $109M | $4.2M | $105M | 26× |
| Other income, net | $2.4M | $3.0M | −$603K | -20% |
| Operating profit | $74.2M | −$37.3M | $111M | — |
| Costs & expenses | $35.0M | $41.5M | −$6.5M | -16% |
| Pre-tax earnings | $76.6M | −$34.3M | $111M | — |
| Research & development | $26.6M | $29.4M | −$2.8M | -10% |
| General & admin | $8.4M | $7.8M | $653K | +8% |
| Net earnings | $76.6M | −$36.1M | $113M | — |
| Operating cash sources | $117M | −$5.9M | $123M | — |
| Depreciation | $3.2M | $3.3M | −$97K | -3% |
| Share-based compensation | $2.4M | $2.7M | −$234K | -9% |
| Cash used in operations | $34.6M | $24.2M | $10.4M | +43% |
| Working capital & other | $117M | −$5.9M | $123M | — |
Questions
How much did Century Therapeutics's revenue grow quarter over quarter in Q1 2025?
Century Therapeutics's revenue rose $105M (26×) from $4.2M in Q4 2024 to $109M in Q1 2025. Operating margin 67.9% against -893.5% (+961.4 pts).